Ace Therapeutics, a contract research organization specializing in translational blood disorder research, has launched a comprehensive suite of integrated preclinical hematology CRO services designed to accelerate the discovery and regulatory advancement of novel therapeutics for a broad spectrum of hematologic diseases. The announcement, made today, highlights the company's expanded preclinical hematology CRO services, which aim to address bottlenecks in model translatability and end-to-end study execution that often hinder developers of gene therapies, biologics, small molecules, RNA modalities, and cell-based treatments for blood disorders.
Hematologic diseases encompass complex pathologies affecting red blood cells, white blood cells, platelets, bone marrow, and lymphatic systems, including inherited anemias, autoimmune blood conditions, coagulation defects, myelodysplastic syndromes, and hematopoietic failure disorders. Traditional preclinical research frequently faces limitations in model translatability and integrated study execution, creating significant challenges for biotech and pharmaceutical companies. Ace Therapeutics addresses these pain points through its vertically integrated framework that unifies in vitro modeling, in vivo efficacy testing, biomarker profiling, PK/PD analysis, safety toxicology, and custom biospecimen analytics.
Central to the new service offering is a robust collection of in vivo hematologic disease models, built across multiple preclinical species including mice, rats, dogs, and non-human primates. The categorized model bank encompasses genetically engineered lines, chemically induced disease platforms, antibody-triggered autoimmune systems, and patient-derived xenograft (PDX) constructs. For genetic hematological disorders, Ace Therapeutics maintains transgenic and knockout mouse models for sickle cell disease, α- and β-thalassemia, G6PD deficiency, and hereditary spherocytosis. Researchers investigating bone marrow failure can access radiation or cyclophosphamide-induced myelosuppression rodents, immune-mediated aplastic anemia lymphocyte transfer models, and FANCA-knockout Fanconi anemia lines.
In addition to in vivo models, the preclinical hematology CRO services deliver cutting-edge in vitro modeling platforms, including biomimetic 3D hematopoietic culture systems that reconstruct bone marrow niche microenvironments, patient-specific iPSC-derived hematopoietic disease lines, and functional assays utilizing primary human CD34+ hematopoietic stem and progenitor cells from bone marrow, cord blood, and mobilized peripheral blood. These tools enable high-throughput, human-relevant mechanistic research.
Beyond model development, the services extend across the full drug development lifecycle, from target identification and CRISPR-based validation to specialized PK/PD profiling tailored to blood disorder therapeutics. Hematology-focused safety pharmacology and toxicology assessments evaluate candidate treatments for impacts on hematopoiesis, clotting function, endothelial integrity, and organ toxicity in blood-rich tissues including the spleen and bone marrow. Specialized technical support is offered for all therapeutic modalities, ranging from small-molecule iron chelators and JAK inhibitors to monoclonal antibodies, LNPs delivering RNA therapeutics, AAV/lentiviral gene vectors, and engineered cell therapies for inherited hemoglobinopathies and bleeding disorders.
All research workflows adhere to standardized operating procedures with rigorous quality control to guarantee reproducible, regulatory-ready data. Clients can collaborate with Ace Therapeutics to design customized study projects, including custom CRISPR-edited animal lines, humanized hematopoietic models, and niche-focused in vitro co-culture systems for rare hematological conditions. This launch positions Ace Therapeutics as a dedicated partner for translational blood disorder research, offering integrated solutions that bridge the gap between discovery and clinical application.
